Abstract:The binding affinities (IC<sub>50</sub>) reported for diverse structural and chemical classes of human β-secretase 1 (BACE-1) inhibitors in literature were modeled using multiple in silico ligand based modeling approaches and statistical techniques. The descriptor space encompasses simple binary molecular fingerprint, one- and two-dimensional constitutional, physicochemical, and topological descriptors, and sophisticated three-dimensional molecular fields that require appropriate structural alignments of varied chemical scaffolds in one universal chemical space. The affinities were modeled using qualitative classification or quantitative regression schemes involving linear, nonlinear, and deep neural network (DNN) machine-learning methods used in the scientific literature for quantitative-structure activity relationships (QSAR). In a departure from tradition, ∼20% of the chemically diverse data set (205 compounds) was used to train the model with the remaining ∼80% of the structural and chemical analogs used as part of an external validation (1273 compounds) and prospective test (69 compounds) sets respectively to ascertain the model performance. The machine-learning methods investigated herein performed well in both the qualitative classification (∼70% accuracy) and quantitative IC<sub>50</sub> predictions (RMSE ∼ 1 log). The success of the 2D descriptor based machine learning approach when compared against the 3D field based technique pursued for hBACE-1 inhibitors provides a strong impetus for systematically applying such methods during the lead identification and optimization efforts for other protein families as well.

Pharmacophore Model Construction of β-Secretase Inhibitors

Pharmacophore model construction of beta-secretase inhibitors

Angiotensin-I-converting Enzyme Inhibitory Peptides: Chemical Feature Based Pharmacophore Generation

Synthesis of Hydroxyethylene-based β-Secretase Inhibitors

Synthesis and Preliminary Evaluation of Peptidomimetic Inhibitors of Human Beta-Secretase

The construction of pharmacophore model for(1,3)-β-D-glucan synthase small molecule inhibitors

Computational Modeling of β-Secretase 1 (BACE-1) Inhibitors Using Ligand Based Approaches

Structure-based Design of Hexahydropyrimidine-5-ols As Novel Non-Peptidic Β-Secretase Inhibitors

Identification Of Novel Bace1 Inhibitors By Combination Of Pharmacophore Modeling, Structure-Based Design And In Vitro Assay

Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors.

Pharmacophore Modeling Studies of Type I and Type II Kinase Inhibitors of Tie2.

Pharmacophore Modeling, Docking Studies, and Synthesis of Novel Dipeptide Proteasome Inhibitors Containing Boron Atoms

Synthesis and activity of hydroxyethylene peptidomimetic inhibitors of human β-secretase

Pharmacophore Identification of Α1a-Adrenoceptor Antagonists

The Discovery of Novel Β‐secretase Inhibitors: Pharmacophore Modeling, Virtual Screening, and Docking Studies

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Construction and Application of Pharmacophore Model of Human Carboxylesterase 2 Inhibitors

Study on the Active Mechanism of Β-Secretase Inhibitors by Molecular Simulations.

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Pharmacophore Identification of Hydroxamate HDAC 1 Inhibitors